Search results for "connective"

showing 10 items of 1122 documents

Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study

2017

AIM To assess the impact of short infliximab (IFX) infusion on hospital resource utilization and costs. METHODS All inflammatory bowel diseases (IBD) patients who received IFX 1 h infusion from March 2007 to September 2014 in eight centers from Southern Italy were included in the analysis. Demographic, clinical and infusion related data were collected. The potential benefits related to the short infusion protocol were assessed both in terms of time saving and increased infusion unit capacity. In addition, indirect patient-related cost savings were evaluated. RESULTS One hundred and twenty-five patients were recruited (64 with ulcerative colitis and 61 with Crohn’s disease). Median duration …

musculoskeletal diseasesmedicine.medical_specialtyObservational StudyCost savings03 medical and health sciences0302 clinical medicineInternal medicinemedicineIn patient030212 general & internal medicineEconomic impact analysisskin and connective tissue diseasesProtocol (science)business.industryInflammatory Bowel DiseasesOne-hour infusionInfliximabInfliximabMulticenter studyCost savingsstomatognathic diseasesEconomic impactMulticenter studyPhysical therapy030211 gastroenterology & hepatologybusinessmedicine.drugWorld Journal of Gastrointestinal Pharmacology and Therapeutics
researchProduct

Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis

2009

Abstract Background Undiagnosed patients with the attenuated form of mucopolysaccharidosis (MPS) type I often have joint symptoms in childhood that prompt referral to a rheumatologist. A survey conducted by Genzyme Corporation of 60 European and Canadian rheumatologists and pediatric rheumatologists demonstrated that Bone and joint manifestations are prominent among most patients with MPS disorders. These life-threatening lysosomal storage diseases are caused by deficient activity of specific enzymes involved in the degradation of glycosaminoglycans. Patients with attenuated MPS disease often experience diagnostic delays. Enzyme replacement therapy is now commercially available for MPS I (l…

musculoskeletal diseasesmedicine.medical_specialtyPediatricscongenital hereditary and neonatal diseases and abnormalitieslcsh:Diseases of the musculoskeletal systemIdursulfaseMucopolysaccharidosisDiseaseRheumatologyInternal medicinemedicineImmunology and AllergyPediatrics Perinatology and Child HealthYoung adultCarpal tunnel syndromeskin and connective tissue diseasesbusiness.industrylcsh:RJ1-570nutritional and metabolic diseaseslcsh:PediatricsEnzyme replacement therapyHypothesismedicine.diseaseRheumatologyJoint painPediatrics Perinatology and Child Healthmedicine.symptomlcsh:RC925-935businessmedicine.drugPediatric Rheumatology
researchProduct

Self-reported flares are predictors of radiographic progression in rheumatoid arthritis patients in 28-joint disease activity score remission: a 24-m…

2016

Background Disease flares are common in rheumatoid arthritis (RA) and are related to structural damage. However, few data on the impact of flares reported by patients on radiographic progression are available. Our aim was to investigate whether overall flares (OF), self-reported flares (SRF) and short flares assessed at the visit (SF) predict radiographic progression in RA patients in DAS28 (28-joint disease activity score) remission. Methods We reviewed the records of RA patients included in our database. We considered all patients who had a period of at least 24 months in remission (DAS28 0. Patients were assessed every 3 months and flares were recorded. We defined SRF as any worsening of…

musculoskeletal diseasesmedicine.medical_specialtyRadiographic progressionRadiographyDiseasenot knownDisease activity03 medical and health sciencesJoint disease0302 clinical medicineInternal medicineDAS28 remissionmedicine030212 general & internal medicineRheumatoid arthritisskin and connective tissue diseases030203 arthritis & rheumatologybusiness.industryFlaresmedicine.diseaseRheumatologyBiologic treatment; DAS28 remission; Flares; Radiographic progression; Rheumatoid arthritis; Self-reported flaresRheumatoid arthritisOrthopedic surgeryPhysical therapyObservational studybusinessBiologic treatmentSelf-reported flaresResearch ArticleArthritis Research & Therapy
researchProduct

The challenge of using the rheumatoid arthritis diagnostic criteria in clinical practice.

2015

The new 2010 ACR/EULAR (American College of Rheumatology/European League Against Rheumatism) criteria of Rheumatoid Arthritis recently published, have been released to classify and identify patients with early RA who could benefit from early therapy. They recommend anti-citrullinated protein antibody (ACPA) testing as an alternative criterion to Rheumatoid Factor (RF) and ACPA that were introduced together with the other classic criteria in a scoring system. We previously criticized these new criteria because of unavailable specificity and sensibility in the first paper, and the use of ACPA as dichotomous criterion (presence/absent) and alternatives to rheumatoid factor. Our previous work p…

musculoskeletal diseasesmedicine.medical_specialtyScoring systemEarly rheumatoid arthritiEarly TherapyPeptides CyclicSensitivity and SpecificityAntibodiesArthritis RheumatoidInternal medicineInternal MedicineMedicineRheumatoid factorHumansACR/EULAR criteriaskin and connective tissue diseasesIntensive care medicineSocieties Medicalbusiness.industryProbabilistic logicmedicine.diseaseLikelihood ratioRheumatologyACR criteriaClinical PracticeEarly DiagnosisRheumatoid arthritisPractice Guidelines as TopicPhysical therapyEmergency MedicineProbabilistic clinical reasoningbusinessRheumatismInternal and emergency medicine
researchProduct

MINIMIZING INFLIXIMAB TOXICITY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

2008

Abstract Background Infliximab is a widely used biological agent for the treatment of inflammatory bowel disease, and has a favorable risk/benefit ratio. Aim It is useful to know that patients treated with infliximab are exposed to developing adverse events that could be reduced with a prudent and a rational clinical approach and by optimizing the treatment protocol. Methods PubMed (including Epub) was searched in October 2006 and again in March 2007. Results The high immunogenic potential of infliximab determines the antibodies that inhibit the effect of infliximab and the appearance of subsequent acute and delayed infusion reactions. Infliximab has an immunomodulatory effect, thus increas…

musculoskeletal diseasesmedicine.medical_specialtyTuberculosisInflammatory bowel diseaseGastroenterologyDrug Administration SchedulePharmacotherapyimmune system diseasesInternal medicinemedicineHumansImmunologic Factorsskin and connective tissue diseasesAdverse effectClinical Trials as TopicHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologyAntibodies Monoclonalmedicine.diseaseInflammatory Bowel DiseasesInfliximabInfliximabLymphomastomatognathic diseasesHeart failureToxicityDrug Therapy CombinationbusinessImmunosuppressive Agentsmedicine.drug
researchProduct

Levetiracetam‐induced pediatric toxic epidermal necrolysis successfully treated with etanercept

2020

Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults, but few cases have been reported in children. To date, only four pediatric cases of TEN treated with infliximab and one with etanercept have been published. We present the case of an 8-year-old boy diagnosed with TEN induced by levetiracetam, successfully treated with etanercept, systemic corticosteroids, and intravenous immunoglobulin.

musculoskeletal diseasesmedicine.medical_specialtybiologybusiness.industryDermatologymedicine.diseaseDermatologyToxic epidermal necrolysisInfliximabEtanercept030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisPediatrics Perinatology and Child Healthbiology.proteinmedicineTumor necrosis factor alphaLevetiracetamAntibodyskin and connective tissue diseasesbusinessmedicine.drugPediatric Dermatology
researchProduct

Abatacept as Adjunctive Therapy in Refractory Polymyalgia Rheumatica.

2021

Glucocorticoids (GCs) are the mainstay of treatment for patients with polymyalgia rheumatica (PMR).1 Despite their efficacy, GCs are associated with well-known adverse events and a substantial proportion of patients with PMR do not respond adequately, or are refractory, to initial GC treatment. GC-sparing agents in PMR are limited to methotrexate (MTX).1.

musculoskeletal diseasesmedicine.medical_specialtyeducationImmunologyGiant Cell ArteritisPolymyalgia rheumaticaAbataceptDiagnosis DifferentialRheumatologyRefractoryimmune system diseasesInternal medicinemedicineImmunology and AllergyHumansskin and connective tissue diseasesAdverse effectbusiness.industryAbataceptmedicine.diseaseCombined Modality TherapyPolymyalgia RheumaticaMethotrexatebusinesshormones hormone substitutes and hormone antagonistsmedicine.drugThe Journal of rheumatology
researchProduct

Celecoxib for recurrent sclerouveitis after syphilitic panuveitis. A case report

2011

Purpose To report a case of recurrent ocular inflammation after optimal therapy of bilateral syphilitic panuveitis responding to oral celecoxib. Methods A case report was conducted. Results A 76-year-old man presented with painful blurry vision in both eyes. Ocular examination disclosed bilateral panuveitis. Serological testing confirmed blood and cerebrospinal fluid syphilitic involvement. After 2 weeks of intravenous penicillin therapy, recurrent episodic sclerouveitis was observed. Conclusion Ocular inflammation after healing of infectious uveitis is a rare ophthalmic sequela. In an immunocompetent patient, either re-infection or immune uveitis should be evoked. Non-steroidal therapeutic…

musculoskeletal diseasesmedicine.medical_specialtygenetic structuresbusiness.industryBrief ReportPanuveitisSclerouveitisDermatologyeye diseasesOphthalmologyInfectious DiseasesCelecoxibBilateral syphilitic panuveitisCelecoxibmedicinelipids (amino acids peptides and proteins)heterocyclic compoundsTreponema pallidumskin and connective tissue diseasesbusinessOcular inflammationmedicine.drugJournal of Ophthalmic Inflammation and Infection
researchProduct

Las bibliotecas de dos alfaquíes borjanos.

2000

Labarta Gomez, Ana Maria - Ana.Labarta@uv.es

musculoskeletal diseasesstomatognathic diseasesCultura escritaMoriscosUNESCO::HISTORIAimmune system diseases:HISTORIA [UNESCO]Mudéjares ; Moriscos ; Alfaquíes ; Cultura escritaskin and connective tissue diseasesMudéjaresAlfaquíes
researchProduct

Problemàtica de les inundacions en la conca baixa del riu Gorgos.

1992

Camarasa Belmonte, Ana - Ana.Camarasa@uv.es

musculoskeletal diseasesstomatognathic diseasesRiu Gorgos:GEOGRAFÍA [UNESCO]immune system diseasesXàbiaPaís ValenciàXàbia ; Marina Alta ; País Valencià ; Riu Gorgosskin and connective tissue diseasesUNESCO::GEOGRAFÍAMarina Alta
researchProduct